English
tipifarnib
Sign in to saveAlso known as Zarnestra
Tipifarnib (INN, proposed trade name Zarnestra) is a farnesyltransferase inhibitor. Farnesyltransferase inhibitors block the activity of the farnesyltransferase enzyme by inhibiting prenylation of the CAAX tail motif, which ultimately prevents Ras from binding to the membrane, rendering it inactive.
Research
480 papers- Tipifarnib Reduces Extracellular Vesicles and Protects From Heart Failure.Circulation research · 2024
- Tipifarnib: farnesyl transferase inhibition at a crossroads.Expert review of anticancer therapy · 2006
- Tipifarnib Inhibits HRAS-Driven Dedifferentiated Thyroid Cancers.Cancer research · 2018
- Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021
- Tipifarnib (Janssen Pharmaceutica).Current opinion in investigational drugs (London, England : 2000) · 2002
via PubMed
Wikidata facts
- Mass
- 488.117066684
Show 4 more facts
- chemical formula
- C₂₇H₂₂Cl₂N₄O
- canonical SMILES
- CN1C=NC=C1C(C2=CC=C(C=C2)Cl)(C3=CC4=C(C=C3)N(C(=O)C=C4C5=CC(=CC=C5)Cl)C)N
- Commons category
- Tipifarnib
- isomeric SMILES
- Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2c(c1)c(-c1cccc(Cl)c1)cc(=O)n2C
Sources (2)
via Wikidata · CC0
~2 min read
Article
5 sectionsContents
- History
- Investigations
- Cancer
- Progeria
- References
Tipifarnib (INN, proposed trade name Zarnestra) is a farnesyltransferase inhibitor. Farnesyltransferase inhibitors block the activity of the farnesyltransferase enzyme by inhibiting prenylation of the CAAX tail motif, which ultimately prevents Ras from binding to the membrane, rendering it inactive.
==History== The compound was discovered by Johnson & Johnson Pharmaceutical Research & Development, L.L.C, with registration number R115777.